1. Home >
  2. M&A >
  3. Venture >
  4. Germany >
  5. EQT Life Sciences Invests In Cardior

Investment Summary

EQT Life Sciences Invests In Cardior

On May 11, 2017, growth capital firm EQT Life Sciences invested in life science company Cardior

Investment Highlights
  • This is EQT Life Sciences’ 8th transaction in the Life Science sector.
  • This is EQT Life Sciences’ 3rd transaction in Germany.
Investment Fate
  • Cardior was sold to a publicly-traded strategic buyer in 2024 for 1.0B USD.

Investment Summary
Date 2017-05-11
Target Cardior
Sector Life Science
Investor(s) EQT Life Sciences
Deal Type Venture

Target

Cardior

Hannover, Germany
Cardior is a clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair, and reverse diseases of the heart. The company's therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. Cardior was founded in 2016 and is based in Hannover, Germany.

Search 215,058 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

EQT Life Sciences

Category Growth Capital Firm
Founded 1987
PE ASSETS 3.5B EUR
Size Large
Type Sector Focused
DESCRIPTION

EQT Life Sciences (formerly Life Science Partners) is a private investment firm focused on growth and venture capital financing for life sciences and healthcare companies. The Firm targets early to mid?stage companies in sectors such as therapeutics, medical devices, diagnostics, healthtech, and biotech. EQT Life Sciences was formed in 1986 and is headquartered in Amsterdam, the Netherlands.

DEAL STATS #
Overall 15 of 47
Sector: Life Science M&A 8 of 30
Type: Venture M&A Deals 12 of 39
Country: Germany M&A 3 of 4
Year: 2017 M&A 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-05-02 Imcheck Therapeutics

Marseilles, France

ImCheck Therapeutics is a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. Its clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rational combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Imcheck Therapeutics was founded in 2015 and is based in Marseilles, France.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-07-19 Simplify

Sunnyvale, California, United States

Simplify is a medical device company focused on cervical spinal disc arthroplasty, using innovative, MRI-compatible materials designed to optimize diagnostic imaging and decrease the need for ionizing radiation. Simplify was founded in 2013 and is based in Sunnyvale, California.

Buy -
Mergr

Solution for

Product

Company

Legal